Osteopontin Preconditioning Improves the Regenerative Effects of Mesenchymal Stem Cells In Vitro but Not Their Therapeutic Efficacy Following Hypoxia-Ischemia in Mice
Cells · 2025
DOI: 10.3390/cells14221824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sara T De Palma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht Universit…. Hauptthemen laut MEDLINE: Osteopontin, Mesenchymal Stem Cells, Hypoxia-Ischemia, Brain, Mesenchymal Stem Cell Transplantation. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Dutch Research Council, Wilhelmina Children's Hospital.
Abstract (Originalsprache)
Hypoxic-ischemic (HI) brain injury is associated with high mortality and severe long-term neurodevelopmental impairments in term newborns. Intranasal mesenchymal stem cell (MSC) therapy is a promising strategy to boost neurorepair after injury, and optimization strategies to further enhance its therapeutic potential are under development. In this study, we explored whether 24 h preconditioning of MSCs with 1000 ng/mL of osteopontin (OPN) could enhance MSC properties in vitro and in vivo. OPN-preconditioned MSCs (OPN-MSCs) showed increased activation of the ERK transcription pathway at 1 h during preconditioning and enhanced migration compared to naïve-MSCs. OPN preconditioning also altered gene expression of neurotrophic and immunomodulatory factors in MSCs. In vitro assessment of MSC potency showed that while OPN-MSCs were as effective as naïve-MSCs in reducing microglia activation, OPN preconditioning enhanced the potency of MSCs to boost neural stem cell differentiation into more complex neurons. However, in vivo, OPN-MSCs were not superior to naïve-MSCs in reducing lesion size in mice when applied at 3 days post-HI. Altogether, OPN preconditioning enhanced the migratory and neurotrophic properties of MSCs in vitro but not in vivo, highlighting its potential to optimize MSC function while underscoring the need for further research to refine in vivo translation and to evaluate functional outcomes for therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3584 EA Utrecht, The Netherlands.
- Department of Neonatology, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3584 EA Utrecht, The Netherlands.
ORCID-Profile: Sara T De Palma, Caroline G M de Theije
Förderung
- European Union
- Dutch Research Council
- Wilhelmina Children's Hospital
- EU
- Wilhelmina Children’s Hospital
Zitieren
APA
De Palma, S. T., van Wijk-Eeftink, C. N., Baak, L. M., Nijboer, C. H. A., & de Theije, C. G. M. (2025). Osteopontin Preconditioning Improves the Regenerative Effects of Mesenchymal Stem Cells In Vitro but Not Their Therapeutic Efficacy Following Hypoxia-Ischemia in Mice. Cells. https://doi.org/10.3390/cells14221824
Vancouver
De Palma ST, van Wijk-Eeftink CN, Baak LM, Nijboer CHA, de Theije CGM. Osteopontin Preconditioning Improves the Regenerative Effects of Mesenchymal Stem Cells In Vitro but Not Their Therapeutic Efficacy Following Hypoxia-Ischemia in Mice. Cells. 2025. doi:10.3390/cells14221824
BibTeX
@article{DePalma2025,
author = {De Palma, Sara T and van Wijk-Eeftink, Celine N and Baak, Lisanne M and Nijboer, Cora H A and de Theije, Caroline G M},
title = {Osteopontin Preconditioning Improves the Regenerative Effects of Mesenchymal Stem Cells In Vitro but Not Their Therapeutic Efficacy Following Hypoxia-Ischemia in Mice},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14221824}
}
EUVIMED